Sign up to save your podcasts
Or
Share Listen to Gynecologic Oncology
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Listen to Gynecologic Oncology
Listen to Gynecologic Oncology episodes
- Do We Have the Courage? Pregnancy, Policy, and the Price Surgeons Pay
Editor's Choice: Pregnancies in gynecologic oncologists: An assessment of pregnancy policies and complications within a surgical subspecialty
Editorial: Pregnancy complications in gynecologic oncologists – A call to action to do betterHosted by:
Paola Gehrig, MD
University of Virginia , Charlottesville, United States of AmericaFeaturing:
Kelsey Goon, MD
University of Chicago, United States of AmericaKathryn A. Mills, MD
University of Chicago, United States of AmericaChristine S. Walsh, MD
University of Colorado School of Medicine, United States of AmericaBrooke Sanders, MD
Washington University School of Medicine, United States of AmericaCheck out more content on the journal's homepage at https://www.gynecologiconcology-online.net
42 min - FIGO 2023 Upstaging: Overtreatment or Overdue Precision?
Editor's Choice: FIGO 2023 staging may result in overtreatment of early-stage endometrial cancer
Editorial: A path to precision in endometrial cancer management: Moving past FIGO 2023Hosted by:
David Gaffney, MD, PhD
The University of Utah, Salt Lake City, Utah, United States of AmericaFeaturing:
Allison Roy, MD
SUNY Upstate Medical University, Syracuse, NY, United States of AmericaJessica N. McAlpine
University of British Columbia, Vancouver, BC, CanadaDavid Mutch
Washington University School of Medicine, St Louis, MO, United States of AmericaCheck out more content on the journal's homepage at https://www.gynecologiconcology-online.net
32 min - ERAS 2026: Key Updates Every Gynecologic Oncologist Should Know
Editor's Choice: Enhanced recovery after surgery (ERAS®) society guidelines for gynecologic oncology: 2026 update
Editorial: The evolving landscape of personalized perioperative care: A commentary on the 2026 ERAS® Gynecologic oncology guidelinesHosted by:
Sean C. Dowdy, MD; Division of Gynecologic Oncology, Mayo Clinic College of Medicine, Rochester, MN, USA
Featuring:
Gregg Nelson, MD, PhD; Department of Obstetrics & Gynecology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
Richard D. Urman, MD; Department of Anesthesiology, The Ohio State University Wexner Medical Center and College of Medicine, Columbus, OH, USA
Olle Ljungqvist, MD, PhD; Department of Molecular Medicine & Surgery, Karolinska Institutet, Stockholm, Sweden
Check out more content on the journal's homepage at https://www.gynecologiconcology-online.net
27 min - Beyond the Binary: Unpacking Molecular Diversity in PMMR Endometrial Cancer
Editor's Choice: Biomarker heterogeneity and efficacy of durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with mismatch repair proficient endometrial cancer: exploratory analyses of the DUO-E/GOG-3041/ENGOT-EN10 trial
Editorial: Hitting the mark—or missing it? The promise and peril of biomarkers in endometrial cancerHosted by:
Amanda Nickles Fader, MD; Johns Hopkins Medicine Baltimore, MD, USA
Featuring:
Kathleen Moore, MD; Gynecologic Cancer Clinic, Stephenson Cancer Center at the University of Oklahoma Medical Center, Oklahoma City, OK, USA
Ramez N Eskander, MD; Department of Obstetrics, Gynecology and Reproductive Sciences, Division of Gynecologic Oncology, UC San Diego, USA
Check out more content on the journal's homepage at https://www.gynecologiconcology-online.net
26 min - Cologuard-like test for identification of endometrial cancer through vaginal sampling
Editor's Choice: Optimization of methylated DNA markers to rule out endometrial cancer in patients with abnormal uterine bleeding
Editorial: Tampon-based methylated DNA testing for endometrial cancer: Promising innovation, but prudence before practice
Hosted by:
Charles N. Landen Jr., MD; University of Virginia Charlottesville, VA, USA
Featuring:
Jamie N. Bakkum-Gamez, MD; Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA
John B. Kisiel, MD; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
Joy M. Davis MD; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Check out more content on the journal's homepage at https://www.gynecologiconcology-online.net
26 min - PARP Inhibitors in Ovarian Cancer: A Society of Gynecologic Oncology Podcast
Updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors in Ovarian Cancer: A society of gynecologic oncology clinical practice review
Moderator:
Ursula A. Matulonis, MD; Dana-Farber Cancer Institute
Speakers:
Bhavana Pothuri, MD; Perlmutter Cancer Center, NYU Langone Health
Róisín E. O’Cearbhaill, MD; Gynecologic Medical Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center; Department of Medicine, Weill Cornell Medical College
Yvette Drew, MBBS, PhD; BC Cancer Centre Vancouver and University of British Columbia
Christina Washington, MD; Stephenson Cancer Center, University of Oklahoma
Ursula A. Matulonis, MD, is joined by Bhavana Pothuri, MD, Róisín O’Cearbhaill, MD, Yvette Drew, MBBS, PhD, and Christina Washington, MD, to discuss recent updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors (PARPi) in ovarian cancer. Based on the recent Society of Gynecologic Oncology clinical practice review published in Gynecologic Oncology, the speakers review the evolving role of PARP inhibitors and the clinical implications of updated regulatory approvals.
The panel explores current evidence supporting PARP inhibitor use in ovarian cancer, including considerations for patient selection, biomarker testing, maintenance therapy, and safety considerations. The speakers also discuss how recent changes in FDA indications may affect clinical decision-making and treatment sequencing in practice.
This podcast highlights practical clinical pearls to help guide practitioners in the appropriate integration of PARP inhibitors into the management of ovarian cancer patients.
This podcast was developed by the Society of Gynecologic Oncology for Gynecologic Oncology.Check out more content on the journal's homepage at https://www.gynecologiconcology-online.net
20 min - Home the Same Day? Testing the Limits in Ovarian Cancer Debulking Surgery
Editor's Choice: Same day discharge after minimally invasive interval debulking surgery in advanced stage ovarian cancer
Editorial: Same-day discharge in advanced ovarian cancer as a milestone of surgical evolution and patient selection
Hosted by:
Gregg Nelson, MD, PhD, FRCSC University of Calgary, Calgary, Alberta Canada
Featuring:
Surabhi Tewari, MD, Department of Obstetrics and Gynecology, Mass General Brigham, Harvard Medical School, Boston, MA, USA
Alexander Melamed, MD MPH, Department of Obstetrics and Gynecology, Mass General Brigham, Harvard Medical School, Boston, MA, USA
Jose Alejandro Rauh-Hain, MD MPH, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Check out more content on the journal's homepage at https://www.gynecologiconcology-online.net
19 min - Recognizing and Managing ADC-Associated Pulmonary Toxicities
Editor’s Choice: Interstitial lung disease in targeted therapies: A Society of Gynecologic Oncology clinical practice statement
Hosted by:
Jose Alejandro Rauh-Hain, MD MPH
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USAFeaturing:
Charles A. Powell, MD, MBA
Division of Pulmonary, Critical Care and Sleep Medicine, Tisch Cancer Center, Icahn School of Medicine at Mount Sinai, New York, NY, USACheck out more content on the journal's homepage at https://www.gynecologiconcology-online.net
30 min - In good SHAPE
Editor's Choice: Comparative outcomes of simple versus radical hysterectomy in patients with and without very low-risk early-stage cervical cancer: An exploratory analysis from the Gynecologic Cancer Intergroup/Canadian Cancer Trials Group CX.5/SHAPE trial
Editorial: Commentary on: Comparative outcomes of simple versus radical hysterectomy in patients with and without very low-risk early-stage cervical cancer: An exploratory analysis from the Gynecologic Cancer Intergroup Canadian Cancer Trials Group Cx.5/SHAPE trial
Hosted by: Gregg Nelson, MD, PhD, FRCSC University of Calgary, Calgary, Alberta Canada
Featuring: Janice S. Kwon MD, MPH, FRCSC, University of British Columbia, Vancouver, Canada and R. Wendel Naumann, MD Atrium Health, Wake Forest University School of Medicine, Charlotte, NC 28203, USACheck out more content on the journal's homepage at https://www.gynecologiconcology-online.net
24 min - ctDNA-Guided PARPi Therapy in Ovarian Cancer
Editor’s Choice: Circulating tumor DNA monitoring in ovarian cancer patients receiving PARPi maintenance therapy: Can we further personalize treatment?
Editorial: Towards personalizing PARP inhibitor maintenance therapy for ovarian cancer
Hosted by:
Ursula Matulonis, MD, Associate Editor of Gynecologic Oncology
Featuring:
Rebecca Arhend, University of Alabama at Birmingham, Birmingham, AL, USA
Christina M. Annunziata, American Cancer Society, Atlanta, GA, USACheck out more content on the journal's homepage at https://www.gynecologiconcology-online.net
26 min
About Listen to Gynecologic Oncology
From the publisher's feed
Stay informed with the latest research and emerging topics in gynecologic oncology through our monthly podcast series. Each episode features a dynamic conversation hosted by one of our Journal’s…
esteemed editors, who speaks with the authors of the Editor’s Choice article and the accompanying commentarial.
More shows like Listen to Gynecologic Oncology
Gynecologic Oncology Update
13 Listeners
The Daily
111,868 Listeners
Ready, Set, GYO!
30 Listeners